Insights
Search Results
Newsletters
1.29.26
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q3/Q4 2025
Wilson Sonsini’s All Eyes on AI: Regulatory, Litigation, and Transactional Developments closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deals highlights, firm publications, and other AI and machine learning highlights. This latest Q3/Q4 2025 edition features:
Newsletters
9.09.25
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q2 2025
The latest edition of All Eyes on AI addresses the White House’s AI Action Plan, the USPTO’s plan to accelerate patent review, the EC’s details of the EU AI Act for GPAI requirements, and the Japanese market’s study on generative AI markets.
News Articles
5.22.25
Lori Westin Named “API Leader of Influence 2025” by San Diego Business Journal
On May 19, 2025, Wilson Sonsini partner Lori Westin was named among the 2025 “Asian Pacific Islander Leaders of Influence” in a special supplement by the San Diego Business Journal. The publication recognizes these industry leaders for their contributions and commitments to the legal industry and their communities.
News Articles
4.24.25
Wilson Sonsini, Attorneys Recognized in Multiple Categories for The Recorder's 2025 CA Legal Awards
On April 24, 2025, The Recorder revealed the winners and finalists of its annual California Legal Awards, honoring the contributions of attorneys and companies leading technology, innovation, and the legal profession. Wilson Sonsini has been recognized as a finalist in the following categories:
Client Highlights
2.03.25
Wilson Sonsini Successfully Represents Impossible Foods in First-of-Its-Kind FoodTech Patent Suit
Wilson Sonsini served as lead counsel for Impossible Foods in a patent infringement litigation alleging infringement of seven Impossible Foods patents covering manufacturing processes, ingredients, and finished products relating to plant-based food containing heme and Impossible’s innovative transgenic yeast used to manufacture that heme. Our team successfully represented Impossible Foods in defense of six inter partes review petitions before the Patent Trial and Appeal Board in 2022 and 2023. Wilson Sonsini defeated the defendant’s motion to dismiss and motion to stay the District Court litigation. The matter was closely watched as the first patent infringement case in the burgeoning foodtech industry. With trial approaching, the parties resolved the matter and released a joint statement that said: “This resolution affirms Impossible Foods’ category leadership and the strength of its product portfolio related to heme.”
Client Highlights
11.25.24
Wilson Sonsini Advises OneSkin on IP Matters Related to Series A
On November 13, 2024, OneSkin, a biotech skin health brand, announced the successful completion of an oversubscribed Series A financing led by Selva Ventures, with participation from PLUS Capital, Unilever Ventures, Able Partners, and former investors SOSV, Meta Planet, and additional investors. The latest round brings the total company funding to $20 million. Wilson Sonsini Goodrich & Rosati advised OneSkin on intellectual property matters related to the transaction and has advised the company on IP matters generally since its founding in 2016.
Client Highlights
11.10.23
Wilson Sonsini Advises Alpine Immune Sciences on $150 Million Follow-on Public Offering
On November 6, 2023, Alpine Immune Sciences, Inc., a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the transaction.
Client Highlights
8.18.23
Firm Secures Federal Circuit Affirmance of PTAB Victory for Palette Life Sciences
On August 16, 2023, the U.S. Court of Appeals for the Federal Circuit affirmed a Wilson Sonsini Goodrich & Rosati victory for Palette Life Sciences, Inc. against two medical-device patents. Palette provides injectable, biodegradable spacers for protecting non-target organs from radiation treatments. Wilson Sonsini successfully challenged the two broad Incept LLC patents at the Patent Trial and Appeal Board (PTAB) on both anticipation and obviousness grounds. Incept appealed both decisions, challenging the anticipation and obviousness analyses, including arguments on teaching away and commercial success. At the Federal Circuit, Judge Schall (joined by Judge Taranto) affirmed the PTAB’s decisions, with a partial dissent from Judge Newman, who would have remanded some of the claims for further consideration by the PTAB. With this win, more cancer patients will have access to this important protective technology.
Wilson Sonsini partner T.O. Kong argued the case at the PTAB and the Federal Circuit, with support from Tasha Thomas, Lori Westin, Rick Torczon, Kathryn Robinson, and Robyn Moriarty.
Wilson Sonsini partner T.O. Kong argued the case at the PTAB and the Federal Circuit, with support from Tasha Thomas, Lori Westin, Rick Torczon, Kathryn Robinson, and Robyn Moriarty.
News Articles
6.28.23
San Diego Business Journal Names Lori Westin to its 2023 “Women of Influence in Law” and “Women of Influence: 50 Over 50” Lists
On June 26, 2023, The San Diego Business Journal released its 2023 “Women of Influence in Law” honorees, which included the recognition of Wilson Sonsini partner Lori Westin. The accompanying profile mentions her current work with Impossible Foods in a "sprawling patent dispute in federal court and the U.S. Patent Trial and Appeal Board, where [she] routinely ranks as one of the 50 most active women lawyers in the country."
Client Highlights
4.19.23
Firm Advises on Patent Matters on GSK’s $2 Billion Acquisition of BELLUS Health
On April 18, 2023, global biopharmaceutical company GSK announced the $2 billion acquisition of late-stage biopharmaceutical company BELLUS Health. Wilson Sonsini Goodrich & Rosati advised BELLUS on patent matters related to the transaction.
Client Highlights
2.14.22
Wilson Sonsini Represents Cellino in $80 Million Series A Financing
On January 25, 2022, Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG—Leaps by Bayer—8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of $96 million in gross proceeds from private financings to date. Wilson Sonsini Goodrich & Rosati represented Cellino in the transaction.
Client Highlights
8.20.21
Wilson Sonsini Advises Vida Ventures on Vigil Neuroscience’s $90 Million Series B Financing
On August 18, 2021, Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90 million Series B financing. The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures, and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures. Wilson Sonsini Goodrich & Rosati represented Vida Ventures in the transaction.
The financing will be used to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. Vigil is developing both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), an essential microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.
The financing will be used to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. Vigil is developing both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2), an essential microglia sensor that mediates responses to environmental signals to maintain brain homeostasis.